Interim report
Page 1
Poly Medicure Limited Regd . Office : 232 B , 3rd Floor , Okhla Industrial Estate , Phase - III , New Delhi - 110 020 ( INDIA ) T : + 91-11-33550700 , 47317000 E : info@polymedicure.com W : polymedicure.com CIN : L 40300DL1995PLC066923 * POLYMED Date : 07 August , 2026 Scrip Code : - 531768 The Manager , BSE Limited , Department of Corporate Services , Phirozee Jeejeebhoy Towers , Dalal Street , Mumbai- 400001 . Scrip Code : - POLYMED The Manager National Stock Exchange of India Limited Exchange Plaza , Plot No. C / 1 - Block - G Bandra Kurla Complex , Bandra ( E ) , Mumbai - 400051 . Subject : Outcome of the Board Meeting of the Company Ref : Compliance of Regulation 30 and 33 of SEBI ( LODR ) Regulations , 2015 Dear Sir / Madam , Pursuant to Regulation 30 and 33 of SEBI ( LODR ) Regulations , 2015 , We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 07th August , 2026 , at Jaipur Marriott Hotel , Ashram Marg , Near Jawahar Circle , Rajasthan , Jaipur - 302015 , India approved the following businesses : 1. Financial Results Unaudited Financial Results ( Consolidate & Standalone ) for the First quarter ended on 30th June 2026 . A signed copy of the above Financial Results ( Standalone & Consolidated ) along with Auditors ' Review Reports thereon is attached herewith as " Annexure - A " 2. Grant of Stock Options Nomination & Remuneration Committee , held on today i.e. August 07 , 2026 approved grant of 1,476 ( One Thousand Four Hundred Seventy Six Only ) Stock Options under the Poly Medicure Limited Employee Stock Option Scheme 2020 , to eligible employees . The disclosure ( s ) as required under Regulation 30 of the SEBI ( Listing Obligations and Disclosure Requirements ) Regulations , 2015 read with SEBI Master Circular No. SEBI / HO / CFD / POD2 / CIR / P / 0155 dated November 11 , 2024 and December 31 , 2024 , for the above mentioned ESOP Grant is enclosed herewith as " Annexure - B " . 3. Allotment of Stock Options Nomination & Remuneration Committee , held on today i.e. August 07 , 2026 approved Allotment of 1,975 Equity Shares having face value of Rs . 5 / -each to its eligible employees of the Company who has exercised the option Under its Employee Stock Option Scheme , 2020 . Plants : Plot No.104-105 & 115-116-117 , Sector - 59 , HSIIDC Industrial Area , Ballabgarh , Faridabad - 121004 , Haryana ( INDIA ) Plot No. 33-34 , Sector - 68 , IMT , Faridabad - 121004 , ( Haryana ) INDIA T : + 91-129-4287000 , 3355070 Scanned with OKEN Scanner
Page 2
Consequent to this allotment, the paid-up Equity Share Capital of the Company stands increased to Rs. 50,68,07,325 (consisting of 10, 13,61,465 equity shares of face value of Rs. 5 each) from Rs. 50,67,97,450 (consisting of 10, 13,59,490 equity shares of face value of Rs. 5 each). The details as required under Regulation 10(c) SEBI (Share Based Employee Benefits Sweat Equity) Regulations, 2021 is Enclosed as" Annexure •C" 4. Re-appointment of Cost Auditors Re-appointment of M/s Jai Prakash & Company as the Cost Auditors of the Company for the Financial Year 2026-27. The information in terms of Regulation 30 read with Schedule Ill - Para A of Part A of the Listing Regulations (as applicable) and SEBI Circular No. HO/ 49/14/14(7)2025-CFD POD2/l/3762/2026 dated January 30, 2026 is enclosed herewith as "Annexure - D". 5. Resignation of Deputy Company Secretary, KMP Mr. Ravi Prakash has tendered his resignation from the position of Deputy Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company to pursue an alternate career opportunities outside the Organization. He tendered his resignation vide letter dated 21 July 2026 and will be relieved from his responsibilities with effect from close of business hours on 10 August 2026. The information in terms of Regulation 30 read with Schedule Ill - Para A of Part A of the Listing Regulations (as applicable) and SEBI Circular No. HO/49/14/14(7)2025-CFD· POD2/l/3762/2026 dated January 30, 2026 is enclosed herewith as "Annexure-E" The Meeting was started at 01.15 P.M. and concluded on 2:20 P.M. Kindly take a note of the same for your further needful and oblige us. Thanking You, Yours Sincerely For Poly Medicure Limited A vinash Chandra Company Secretary M. No. A32270 Q; Scanned with OKEN Scanner
Page 3
POLY MEDICURE LIMITED ·,>IPOLYMED Regd. Office: 2328, 3rd floor, Okhla Industrial Estate Phase III, New Delhi - 110 020 Website: www.polymedlcure .com, E-mall: lnvestorc11re@polymedlcure.com, CIN: L40300DL1995PLC0669:z3 STATEMENT OF UNAUDITED STANDALONE AND CON SOU DATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 standalone Consolidated Particulars Quartet Ended Quarter Ended 30.06 .2026 31.03.2026 30. 06.2025 30.06.2026 31.03.2026 30.06.2025 (Unaudited} (Audited) {Unaudited) (Unaudited) {Audited) (Unaudited) l Income a Rl!\lenuc from operations 43,109 .95 44,301.49 38,404 .67 52,537 .55 53,451 .11 40,321.07 b Ottler income 7,864.96 1,512 .19 4,109 .55 3,340 .90 1,715.65 4,169 .09 Total income (A) 45,974.91 45,813.68 42,514.22 55,878.45 55,226.79 4"4,490.16 2 Expense,s a Cost of matt'O<IIS consuned 15,274 .60 13,696.45 12,874.86 18,387 .50 15,507 .80 14,107.35 b Purrnases of stock-in-trade 177.12 136.08 85.85 267.46 138.42 85.85 C Q\anges in inventones of finished goods, wort -in-progress and stock-in-trade (3,172 .15) 953.25 (755.28) (4,680 .08} 2,169.97 (1,470 .17) d Employee benefits e,c:pense 8,890 .80 7,810.19 6,921.40 12,690 .29 12,614.10 7,439 .74 e Research and development expenses - 788.01 766.14 726.30 789,11 674.29 728.45 f Finance cost 438 .46 389.20 281.38 650 .14 640 .86 295.01 9 Depreciation and amortisation expense 2,647.00 2,550.70 2,295.49 3,625 .28 3,823.20 2,337 .02 h Othef expenses 9,067 .13 8,831.05 8,377 .81 12,573.51 11,306 .83 8,804 .71 Total expen .ses (B) 34,110.97 35,133.06 30,807.81 44,303.21 46,875.47 32,327.96 3 Profit before share of profit of associate, exceptional Item and tax (A-8) 11,863.94 10,680.62 11,706.41 11,575.24 8,351.32 12,162.20 4 Share ~ Profit of an associate - - - 155.33 170.90 132.43 Pn:,fit befure eroeptional item and tn 11,863.94 10,680.62 11,706.41 11,730.57 8,522.22 12,294.63 s Exceptional item Impact of labour Codes - - - 6 Profit before tax 11,863.94 10,68 0.62 11,70&.41 11.no.57 8,522.22 12,294.63 7 Tax expense a Current tax 2,506 .74 2,32J .31 2,130.98 2,816 .11 2,524 .29 2,206 .81 b Deferred tax 543.91 275.29 782.54 386.07 (526 .02) 779 .53 C Earlier year ta.ices 0.96 19.85 - 0.96 19.8S - Total tax expense 3,051.61 2,618 .45 2,913.52 3,203.14 2,018.12 2,986.34 • Prvfttaftet'tax 8,812.33 8,062.17 8,792.89 8,527.43 6,504.10 9,308.29 9 Other comprehensive income Items that will not be reclassified to profit Of' loss : Remeasurements of defined benefit obligations (90.94) 83.97 (117.32) (90.94) 83.97 {117.32) Tax impacts on abolle 22.89 (21.14) 29.53 22.89 (21.14) 29.53 Items that will be recl~fied to profit Of" loss in subsequent period: Exchange differences on translation ol financial statements ol roreign Subsidiaries - - - 63.73 2,426 .97 19.07 Tax impacts on above . Total other comprehensive IIIC'Olne (68.05) 62.83 (87.79) (4.32) 2,489.80 (68.n) 10 Total comprehensive Income (a,mprislng profit after tax and other 1,744.28 8,125.00 8,705.10 8,523.11 8,993.90 9,239.57 com Income •fter tad 11 Net prvfit attributable to: Equity holders r:/ the parent ~...,,,.." ,. ri, ,.... ..... - - 8,602.52 6,629.19 9,308.29 Non-controlling inlet"~ ~.:, ........ _~ 0 ~ - - (75.09) (125 .09) - f/_'v/ ..i.·· vvv.: ""'~" 12 Other comprehensive Income .attributable to: I •,;:;;,-.. I~\~ , Equity holders of tne parent I 0 l NAYrOel •' I en J - - (4.35) 2,492.99 (68.72) Non~ontroUing interests ' / \('),\ - ; ....... , - - 0.03 (3.19} - L/ ~QI .... .,........._ ~"'_,'b'// ./7 , n ,I ~BdAcc<>~ { ft:A - ~\_ -- An (~ in lacs except per share data) Standalooe Consolidated Year Ended Year Ended 31.03.2026 31 .03.2026 ( ALKfrt:.ed) (Audited) 1,66,246 .18 1,87,525.92 11,991.77 12,008.22 1,78,238.25 1,99 ,534.14 53,885 .50 59,9 38.70 503.71 506.05 {1,339.64) (763.63) 31,314 .62 40,225-59 2,980 .30 2,987.59 1,343 .32 1,829 .07 9,789 .82 11,551.66 34,291.11 40,399 .97 1,32,768.74 1,56,675.00 45,469.Sl 42,859.14 - 568.37 45,469.51 43,427.51 680.40 680.40 44,789.11 42,747.11 9,657 .70 10,115 .84 1,502.75 528. 11 30.17 30.17 11,190.62 10,674.12 33,598.49 32,072.99 30.23 30.23 (7.61) (7.61) - 4,6?5.97 - 22.62 4,648.59 33,621.11 36,721.58 - 32,213.96 - - (140 .97) ~,c...ul,' ~ rtuY/ ' .,~ ff!:.{ - I\--: 14,651.68 I -1New9e1r l !' :i, 1 (3.09} T..,\ 'I- '~~~ ~ Q} Scanned with OKEN Scanner
Page 4
13 Total comprehensive income attributable to; Equity holders of the parent - - - 8,598.17 9, 122.18 9,239.57 - 36,865.64 Non-controlling int erests - - - (75.06) (128.28) - (144.06) 14 Paid-up equity share capital (Face Value of~ 5 e;,ch) 5,067.97 5,067 .97 5,066.29 5,067.()7 5,0fi'l.97 5,066.29 5,067.97 5,067 .97 15 Reserve excluding Revaluation Reserves as per 1);11ance sheet of previous accounting 3,00, 20'.3.27 3.0~.549.30 1vear 16 Earnings per share (Quarterly nol annualised) : &,sic ( ' } 8.69 7.95 8.68 8.49 6.51 9.19 33.15 31.79 Diluted ( '} 8.66 7.95 8.C,7 8.48 ~ 6.5) 9.17 31.12 31.75 ....0 __ _,U)'._ tvB'CUJ?~ <:. ~ ! ~ New Delhi ~ ~ 'I 0 0~ ~ * L o~ Scanned with OKEN Scanner
Page 5
Notes~ The above unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee & approved by the Board of Directots at their respective meetings held on 7th August, 2026 and have also been limited reviewed by the statutory auditors of the Company. The statutory auditors have expressed an unmodified review report on these standalone and consolidated financial results. . 2 The standalone and consolidated financial results have been prepared in accordance with the principles and procedures of Indian Accounting Standards ("Tnd AS") as notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013. 3 The consolidated financial results of the Company and its foreign subsidiaries/Indian subsidiary ("Group") and associate have been prepared as per 1ND AS 110 "consolidated Financial Statements" and IND AS 28 on "Investment in Associates". The entities whose limited reviewed and management certified financial statements have been included in consolidated financial statements are as annexed. 4 In line with the provisions of Ind AS 108 ~Operating Segments" and on the basis of review of operations being done by the management of the Company, the operations of the group falls under medical devices, which is considered to be the only reportable segment by the management. S During the quarter ended 30th )une, 2026, Polymecl Brazil LTDA, a wholly owned subsidiary cnrnpany has acquired 100% equity in Medyneo Comerdo De Produtos Para Saude LTDA at a total consideration oft 34.08 lacs effective from 29th April, 2026. 6 The Hon'ble NO.T of Allahabad has approved the resolution plan submitted by the Company for Himalayan Mineral Waters Private Limited (Target Company) vide Order dated 12th August, 2025 as resolution applicant under corporate insolvency resolution process of Insolvency and Bankruptcy Code (IBC Code) 2016. During the quarter ended 30th June, 2026, upon suspension ot the monitoring committee, the Company has assumed control in accordance with Ind AS 110 over the operations of the target company, however change in directorship and change in shareholding is pending as at the date of financial statements, accordingly target company has become the wholly owned subsidiary of the Company and profit and loss statement for the period ended 30th June, 2026 have been consolidated in consolidated financial statements. 7 During the previous year ended 31st March, 2025, the Company had issued 53,19,148 equity shares of, 5/- each at premium or, 1,875/- each (is.sue price per share t 1,880/- each) amounting to l 99,999.98 lacs to Qualified Institutional Investors on QIP basis and allotment was completed on 22nd August, 2024. The proceeds of QIP have been utilized as per objects of is.sue and the unutirised amount of, 46,S05.35 lacs have temporarily been invested in liauld mutual funds/FD/bonds and balance amount in QIP account is, 7.10 lacs. 8 During the quarter ended 30th June, 2026, 17,500 equity shares at a face value of~ 5/- have been granted to eligible employees in pursuance of Employees Stock Option Scheme 2020 at an exercise price of , 100/- per share. 9 The financial results lndude the results for the quart~ ended March 31,2026 being the balancing figures between the audited figures in respect of full financial year ended 31st March 2026 and the published unaudited year to date figures upto the third quarter of the previous financial year. 10 Previous period figures have been regrouped wherever necessary to conform to the current year dassification. The unaudited results of Poly Medicure Limited for the quarter-ended 30th June 2026 are available on our website, www.polymedicure.com and on the Stock Exchange website www.nseindia.com ~ lb:==-::::-.... 11 bsei di Un www. n a.mm. O · 1 ~ "'" ( .. ~ N wDelhi ~ "1) ::; o * o"' ' PIKe : Jaipur Date : 7tti August 2026 ().} Scanned with OKEN Scanner
Page 6
List of entities included in the consolidated financial statements for the quarter ended 30th June, 2026 are as under : Sr. No. Name of the Company - .,_,_ - --- -~-.. - ·- - .. ~-·-------- , __ ._I Parent_Company 1 1 Poly Med i cure Limited ·--- Subsidiary 2 Plan 1 Health India Private llmlted (ll --·- -•- -- -- - ------ 3 Poly Medicure (lalyang) Company Llmlted 111 4 Po)y Medlcure B.v.01 s Pol~J.e_d Brazll LTDA111 6 Himalayan Minera l Wate rs Private Umited 111 Step - subsidiary 7 I Plan 1 Health SRL(21 • - ---- ~-. 8 Rlsor Holding B.V.12l 9 ,Well inq Med ical B.v.!3l 10 lpe~dracare Holding B.v.<3J 11 Pendracare Vascular B.v.<4l - . - 12 I Pendracare Internationa l B.v.!4l 1-- 1Meqistream SA121 13 -14 Citieffe SRL(si -~ __j_Citieffe lnc.(6l 16 Citi_effe De. (Gl 17 Polv Health lnc.(21 18 Polv Health Limited 121 19 Medyneo Comercio De Produtos Para Saude LTOA171 Associate 20 Ultra For Medical Products Company (Ultra Med) Ill Wholly-owned subsidiary of Poly Medicure Limited 111 Wholly-owned subsidiary of Poly Medicure B.V. 131 Wholly -owned subsidiary of Risor Holding B.V. l 4 l Wholly -owned subsidiary of Pendracare Holding B.V. 151 Wholly-owned subsidiary of Medistream SA (GJ Wholly-owned subsidiary of Citieffe SRL 171 Wholly-owned subsidiary of Polymed Brazil LTDA Country of Holding ~son Holding as on Incorporation June 30, 2026 March 31, 2026 . lndla 100% 100% China 100% 100% Netherlands 100% 100% Brazil 100% 100% lndla - - Italy 100% 100% Netherlands 90% 90% Netherlands 100% 100% Netherlands 100% 100% Netherlands 100% 100% Netherlands 100% 100% Switzerland 100% 100% Italy 100% 100% USA 100% 100% Mexico 100% 100% USA 100% 100% UK 100% 100% Brazil 100% - Egypt 23% 23% a~ Scanned with OKEN Scanner
Page 7
DOOGAR & ASSOCIATES Chartered Accountants lnMpendcnt Auditors ' lk\'irw llcport on the Qunrlerly UnsrncJltcd Stnndafonc Financial Results or the Company pursunnt to lkguln11on 33 of the Securities nnd Exchnngc non rd or fndln (Ll11tlng Obligations and Disdosure Requirements) Rcgnl11llom11 201~ ns nmendctJ To Board or Directors Poly Medicurc Limited 232-B. lllrd Floor, Okhla Industrial E tate. Pha c-111, New Delhi- l l 0020 We have reviewed the accompanying statement of unaudited standalone financial results of Poly Medicure Limited ("tl1e company") for the qua1ter ended 30th June 2026 attached herewith, being submitted by the company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20 IS (as amended). This statement is the responsibility of the Company's Management and approved by the Board of Directors has been compiled from the related interim linancial statements which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information perfonned by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not expr~ss an audit opinion. Attention is drawn to the fact that the figures for the three months period ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures 1n respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular dated 5~1 July, 2016 including the manner in which it is tu be disclosed, or that it contains any material misstatement. For Doogar & Associates Chartered Accountants Firm Registration No. 0005 ~ Madhusu an Ag Partner ~.,.,. ~~ Membership No. 086580 ~red M"'0 UDIN: J- & 0 'fr· 6 15 g O O l- r )< 'f (17 7 ~ ~ Place: Jaipur Date: 07 August 2026 13, Community Centre, East of Kailash, New Delhi - 110065 E-mail : client@doogar.com, admin@doogar.com, Website : www.doogar.com Ph. : 011-46579759,41051966,47037656 Branches at: Mumbai and Agra o~ Scanned with OKEN Scanner
Page 8
DOOGAR & ASSOCIATES Chartered Accountants Independent Auditors' Re,•kw Report on the Qunrlerly Unnudited Consolidated Financial Results of the Company pursuant to Regulnllon 33 of the Securities nnd Exchnnge Bon rd of Ind In (Listing Obligations and Disclosure Requh-ementli) Regulntlon51 2015 R!I nrnemted To Board of Directors Pol)' Medicure Limited 232-0 lllrd Ploor. Okhla Industrial Estate, Phase-111, New Delhi- 110020 l. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Poly Medi cure Urn ited (" Parent'') and its subsidiaries (the parent and its subsidiaries together ref erred to as 'the group') and its share of the profit afler tax of its associate for the quarter ended 30th June 2026 (the "St:itement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended ('the Regulation') read with SEBT Circular No. CIR/CFD/CMDl/44/2019 dated March 29, 2019(' the Circular'). 2. Thi$ Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review. 3~ We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Regulution, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the statement. 5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit. 6. We did not review the financial results of 2 foreign subsidiaries namely Poly Medicure (Laiyang) Co. Limited, China and Polymed Brazil LTDA (consolidated) and one wholly owned subsidiary incorporated in India namely Himalayan Mineral Waters Private Limited included in the consolidated unaudited financial results, whose financial results without elimination reflects total revenue of Rs. I 59.68 Lacs. total net profit/ (loss) after tax of Rs. ( 181.56) Lacs and total comprehensive income/ (loss) of Rs. ( 181.56) lacs, for the quarter ended 30lh June 2026, as considered in the consolidated unaudited financial results. The consolidated ·unaudited financial results also include the Group's share of profit aflel' tax of Rs. 155.33 lacs, for the quarter ended 30th June 2026, as considered in the statement, in respect of one foreign associate, whose financial results have not bee.n reviewed by us. These financial results are certified by the management of respective companies and OLH' conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these ~~~ ·md associate ~ OC' 0~ • Dos ✓, . • 0 ~· o-.,.. 0 ~ ..r ('\\ o No w * * q ;? .,,,.t. ~:-" 13, Community Centre, East of Kailash, New Delhi -"'e \S E-mail : client@doogar.com, admin@doogar.com, Website : www.doogar.com Ph. :011-46579759,41051966,47037656 Branches at : Mumbai and Agra 0 1 Scanned with OKEN Scanner
Page 9
is based solely on the basis of tinnncial statement ns ccrti lied and procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is no( modifictl in respect or rihove matter. We did not review the onsolldoted r:inancial Statement of one foreign subsidiary namely Poly Medicure BV Netherlands for the quarter ended 301h June 2026. which includes financial statemc11ts of Plan 1 Health RL Ttnl)1 for quor1cr ended 31 Morch 2026 ond whose financial statement without elimit1ation reflect total revenue of Rs. 2838.09 Ines, Net pr<)fit n1\cr tax of Rs. 192.06 Ines and total comprehcn ive income/ (loss) of Rs. 192.06 lacs for the qm111er ended 31 March 2026 and have been limited reviewed hy auditor situated out ide lndin and nl $0 includes financial statement of Poly Health Medical fnc. US, Poly Health Limited UK. Risor Holding B.V. etherlands (consolidated) anti Mc<listream SA Switzerland (consolidated), whose financial statement without climinntion reflect total revenue of Rs. 8,474.45 lacs, total rrofit/ (loss) after tax of Rs. (4 l 1'-00) lacs and total comprehensive income/ (loss) of Rs. (418.00 ) lacs for the quarter ended 30 June 2026 ·and have been management certified and given effect to in consolidated financial statements. Our opinion on consolidated financial statements In so far as it relates to the aforesaid subsidiary is based on limited n:view report of one step down subsidiary and management certified financial statements of other ste~ down subsidiaries. Our conclusion on the statement is not modified in respect of above matter. 7. In respect of subsidiaries and associate located outside India whose financial resullc, and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and are management certified/ limited reviewed. The Parent's management has converte.d the financial results of such subsidiaries and associate located outside India from accounting principles generally accepted in their respective countries to the accounting principles generally accepted in India. We have reviewed conversion adjustments made by the parent's management. Our conclusion in so far as it relates to balances and affairs of such subsidiaries and associate located outside India is based on the conversion adjustments prepared by the management of the Parent and reviewed by us. 8. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial statements as limited reviewed/ certified by the management referred to paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid in the aforesaid lndian Accounting Standard specified under Section 133 of Companies Act, 2013, as_ amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, h.Js not disclosed the information required to be disclosed in tenns of ,Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Doogar & Associates Chartered Accountants Finn's Registration number: ~ nga •a Partner Membership number: 086580 /J ' / \ j" 1 urnN : 2-, 0 8 6 r- J-o T k. J-f 11\1 r ~ Place: Jaipur Date: 07 August 2026 a~ Scanned with OKEN Scanner
Page 10
Annexure-1 List of cntitie~ includtd in the tonsolldatcd flnnnclnl stntemcnt9 for the qunrter ended 30th June, 2026 are ns under: Sr. No. Name of the Compnny Pnrent Compnny 1 Poly Me-dicurc Limited Subsidiary 2 Plan 1 Health India Private Limited<ll j Poly 1edicure (Lai yang) Company Limiled'11 4 Poly Medicure B.V.11 ) 5 Polymed Brazil L"lUA11 l 6 Himalayan Mineral Waters Private LimitedC1l Step - subsidi:1ry 7 Plan I Health SRU2l 8 Risor Holding B.V.(2) 9 Wellino Medical B.v.m ' 10 Pendracare Holding B.V.()} 11 Pendracare Vascular B.v.c4> 12 Pendracare International B, V. (4l 13 Medi stream SA (2> 14 Citieffe SRU5> 15 Citieffe lnc.16> 16 Citieffe De.<61 17 Poly Hcallh Inc.m 18 Poly Health LimitedC2> 19 Medyneo Comercio De Produtos Para Saude L TOA l7l Associate 20 Ultra For Medical Products Company (Ultra Med) (') Wholly-owned subsidiary of Poly Medicure Limited <2J Wholly-owned subsidiary of Poly Medicure B.V. Ol Wholly-owned subsidiary ofRisor Holding B.V. (4 l Wholly-owned subsidiary of Pendracare Holding B. V. csi Wholly-owned subsidiary of Medi stream SA C6l Wholly-owned subsidiary of Citieffe SRL (7) Wholly-owned subsidiary of Polymed Brazil Country of incorporntlon -India China Netherlands Brazil India -Italy Netherlands Netherlands Netherlands Netherlands Netherlands -Switzerland Italy USA Mexico USA UK Brazil - Egypt 0} Scanned with OKEN Scanner
Page 11
Annexure - B DISCLOSURE AS PER LISTING REGUl.ATIONS READ WITH SEBI CIRCULAR NO .SEBVffO/CFD/PoDZ/Cll1/l'/0155 DATED NOVEMUER 11, 2024 AND DECEMBER 31, 2024 Grant of Sto<;k OpHon Sr. No. Particu1ars Remarks 1. Brief details of Options 1,476 Options granted by the Nomination & 2. 3. 4 . . 'S. 6. 7. Granted Remuneration Committee in its meeting held on today i.e. on August 07, 2026) to the Employees as defined under the Scheme. Whether the scheme is in Yes terms of SEBI (SBEB) Regulations, 2021 Total number of shares covered by these options Pricing formula Stock Options granted un~er the aforesaid Grant covers 1,476 Equity Shares. 1 Option shall be entitled for conversion to only 1 Share of the Company, subject to the terms of the Scheme. Pursuant to the applicable provisions of the SEBf (SBEB) Regulations 2021 and as per provisions of the existing 1 ESOP Plan', the ESOPs have been granted at a price of INR 100/- i.e. discounted price to the latest available closing price prevailing on the Stock-Exchange on Friday, August 071 2026. Options Vested Not Applicable Tifne within which option Exercise period shall not exceed 3 (Three) months may be exercised from relevant Vesting date and the date after which the Options shall lapse, unless the said period is extended by the Committee in exceptional circumstances. The Options shall not Vest for a period of one year from the date of Grant. Upon the expiry of one year, the Vesting of Options shall take place over a maximum. term of (4) four years as per the Scheme. Options exercised Not Applicable 01 Scanned with OKEN Scanner
Page 12
8. Money realized by exercise Not Applicable of Options 9. The total number of shares Not Applicable arising as a result of exercise of option 10. Options la_psed Not Applicable 11. Variation of terms of Not Applicable Options 12. Brief details of significant The Emp]oyee Stock Option Scheme is tem1s administered by the Nomination and Remuneration Committee of the Company . The grant of Options is based upon the . eligibility criteria as mentioned in the Scheme. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and appJicable taxes in accordance with terms and conditions of the Scheme. 13. Subsequent changes or Not Applicable cancellation or exercise of such options 14. Diluted earnings per share Not Applicable pursuant to issue of equity shares on exercise of options. Annexure-C Regulation 10( c ) Certified true copy of Notification for issue of shares under Regulation 10 (c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. S. Particu]ars Information --- No 1 Company Name and Address of Registered Poly Medicure Limited and Office Registered Office Address: 2328, Third Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020 Q} Scanned with OKEN Scanner
Page 13
2 Name of the Exchc1t1ge on which the Bombay Stock Exchange (BSE) and Company's shares are listed National Stock Exchange (NSE) 3 Filing date of the Statement referred in clause 16.12.2022 22.1 b of guidelines with Stock Exchange 4 Filing Number , if any 164383 5 Title of the Stock Option Scheme pursuant to Employee Stock Option Scheme, 2020 which shares are issued, if any 6 Kind of Security to be listed Equity Shares 7 Par value of the Shares Rs. 5/-each 8 Date of issue of shares August 07, 2026 9 Number of shares issued 1,975 F,quity Shares 10 Share certificate no, if applicable NOT APPLICABLE 11 Distinctive number of the shares, if applicable From 101359491 to 101361465 12 IS[N Number of the shares if issued in Demat INE205C01021 13 Exercise Price per shares Rs. 100/- per share 14 Premium per share Rs. 95/- per share 15 Total issue shares after this issue Equity Shares: - 10,13,61,465 16 Total issue Share Capital after this issue Equity Shares: - 50,68,07,325 17 Detail of any lock-in on the shares N.A 18 Date of expiry of lock-in N.A 19 Whether shares incidental in all respects to The shares are incidental in all existing shares, if not, when they become respects to existing shares. identical? 20 Details of Listing Fee, payable N.A Q:: Scanned with OKEN Scanner
Page 14
Annexure- D REQUIRED DISCLOSURES/DETAILS UNIJER ItEGULA TION 30 OF THE SECURITIES AND EXCHANGE BOARD O1~ INDIA (LISTING OBLIGATIONS AND DISCI.OSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGULATIONS") READ WITH APPLICABLE SEBI CIRCULAR Appointment o{ Cost Auditor(s) S.No. 1. 2 3. 4. Particular Reasons for change viz appointment/ reappointment, Date of Appointment/ Re-appointment & term of appointment/ reappointment M/s. Jai Prakash & Company, Cost Accountants Re-Appointment Re-appointment of M/ s. Jai Prakash & Company, Cost Accountants for the Financial Year 2026-27. Brief Profile (in case of M/s Jai Prakash & Co, Cost Accountant firm was· appointment) established in year 2006. The firm is managed by Cost Accounting professionals with high integrity. We are a team of strongly motivated and young entrepreneurs. By applying modern management techniques, we ensure on-target delivery of our assignments. Disclosure of relationships between directors (in case of appointment of a director) At present we are providing services to the Esteemed Companies belonging to various industries i.e. Pharmaceuticals, Iron & Steels, Auto Parts and Accessories, Electrical & Electronics, Engineering, Chemicals, Textiles, Construction, Rubbers, Railways. NA Q1 Scanned with OKEN Scanner
Page 15
Annexure- E REQUIRED DISCLOSURES/DETAILS UNDER REGULATION 30 OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGULATIONS'') READ WITH APPLICABLE SEBI CIRCULAR Details of cessation of Mr. Ravi Prakash as Deputy Company Secretary and Compliance Officer of the Company S.No. Particular Details Reasons for change viz Resignation 1. appointmentfreappointmer1t, resignation, removal, death or Mr. Ravi Prakash has tendered his resignation othe~.ise from the position of Deputy Company Secretary of the Company vide his letter dated 21.07.2026 to pursue an alternate career opportunities outside the Organization. Date of appointment/ reappointment! cessation (as 2. applicable) & term of 10.08.2026 ei,i,ointrnenttre eppoir,tment Brief Profile (in case of appointment) 3. NA Disclosure of relationships between directors (in case of 4. appointment of a director) NA Q1 Scanned with OKEN Scanner
Page 16
Date: 21.07.2026 To, The Team Manager. Poly Medicure Limited 232-B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi-110020 I hope you are all doing well. • Please accept this email as my formal resignation from my position, effective today. As per my employment terms, my notice period Is two months. However, due to personal reasons, I request your consideration for a shorter notice period and kindly request to be relieved from my duties by 10 August 2026. I sincerely appreciate the opportunities, guidance, and support I have received during my time with the team. Working alongside all of you has been a valuable experience, and I am grateful for the learning and professional growth. I will ensure a smooth transition by completing my pending responsibilities and providing all necessary handovers before my last working day. I kindly request your approval for my early release on 1 0 August 2026. Thank you for your understanding and support . Wishing the team continued success in all future endeavour's. Thanks & Regards, ~'<~ \ Ravi Prakash Deputy Company Secretary Q1 Scanned with OKEN Scanner